tetano
Editor, Senior Moderator
LoS One
. 2022 Apr 25;17(4):e0267235.
doi: 10.1371/journal.pone.0267235. eCollection 2022.
Chromogranin A plasma levels predict mortality in COVID-19
Rebecca De Lorenzo[SUP] 1 2 [/SUP], Clara Sciorati[SUP] 1 [/SUP], Giuseppe A Ramirez[SUP] 1 2 [/SUP], Barbara Colombo[SUP] 3 [/SUP], Nicola I Lorè[SUP] 1 4 [/SUP], Annalisa Capobianco[SUP] 1 [/SUP], Cristina Tresoldi[SUP] 5 [/SUP], Bio Angels for COVID-BioB Study Group; Daniela M Cirillo[SUP] 1 4 [/SUP], Fabio Ciceri[SUP] 2 5 [/SUP], Angelo Corti[SUP] 2 3 [/SUP], Patrizia Rovere-Querini[SUP] 1 2 [/SUP], Angelo A Manfredi[SUP] 1 2 [/SUP]
Affiliations
Abstract
Background: Chromogranin A (CgA) and its fragment vasostatin I (VS-I) are secreted in the blood by endocrine/neuroendocrine cells and regulate stress responses. Their involvement in Coronavirus 2019 disease (COVID-19) has not been investigated.
Methods: CgA and VS-I plasma concentrations were measured at hospital admission from March to May 2020 in 190 patients. 40 age- and sex-matched healthy volunteers served as controls. CgA and VS-I levels relationship with demographics, comorbidities and disease severity was assessed through Mann Whitney U test or Spearman correlation test. Cox regression analysis and Kaplan Meier survival curves were performed to investigate the impact of the CgA and VS-I levels on in-hospital mortality.
Results: Median CgA and VS-I levels were higher in patients than in healthy controls (CgA: 0.558 nM [interquartile range, IQR 0.358-1.046] vs 0.368 nM [IQR 0.288-0.490] respectively, p = 0.0017; VS-I: 0.357 nM [IQR 0.196-0.465] vs 0.144 nM [0.144-0.156] respectively, p<0.0001). Concentration of CgA, but not of VS-I, significantly increased in patients who died (n = 47) than in survivors (n = 143) (median 0.948 nM [IQR 0.514-1.754] vs 0.507 nM [IQR 0.343-0.785], p = 0.00026). Levels of CgA were independent predictors of in-hospital mortality (hazard ratio 1.28 [95% confidence interval 1.077-1.522], p = 0.005) when adjusted for age, number of comorbidities, respiratory insufficiency degree, C-reactive protein levels and time from symptom onset to sampling. Kaplan Meier curves revealed a significantly increased mortality rate in patients with CgA levels above 0.558 nM (median value, log rank test, p = 0.001).
Conclusion: Plasma CgA levels increase in COVID-19 patients and represent an early independent predictor of mortality.
. 2022 Apr 25;17(4):e0267235.
doi: 10.1371/journal.pone.0267235. eCollection 2022.
Chromogranin A plasma levels predict mortality in COVID-19
Rebecca De Lorenzo[SUP] 1 2 [/SUP], Clara Sciorati[SUP] 1 [/SUP], Giuseppe A Ramirez[SUP] 1 2 [/SUP], Barbara Colombo[SUP] 3 [/SUP], Nicola I Lorè[SUP] 1 4 [/SUP], Annalisa Capobianco[SUP] 1 [/SUP], Cristina Tresoldi[SUP] 5 [/SUP], Bio Angels for COVID-BioB Study Group; Daniela M Cirillo[SUP] 1 4 [/SUP], Fabio Ciceri[SUP] 2 5 [/SUP], Angelo Corti[SUP] 2 3 [/SUP], Patrizia Rovere-Querini[SUP] 1 2 [/SUP], Angelo A Manfredi[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35468164
- DOI: 10.1371/journal.pone.0267235
Abstract
Background: Chromogranin A (CgA) and its fragment vasostatin I (VS-I) are secreted in the blood by endocrine/neuroendocrine cells and regulate stress responses. Their involvement in Coronavirus 2019 disease (COVID-19) has not been investigated.
Methods: CgA and VS-I plasma concentrations were measured at hospital admission from March to May 2020 in 190 patients. 40 age- and sex-matched healthy volunteers served as controls. CgA and VS-I levels relationship with demographics, comorbidities and disease severity was assessed through Mann Whitney U test or Spearman correlation test. Cox regression analysis and Kaplan Meier survival curves were performed to investigate the impact of the CgA and VS-I levels on in-hospital mortality.
Results: Median CgA and VS-I levels were higher in patients than in healthy controls (CgA: 0.558 nM [interquartile range, IQR 0.358-1.046] vs 0.368 nM [IQR 0.288-0.490] respectively, p = 0.0017; VS-I: 0.357 nM [IQR 0.196-0.465] vs 0.144 nM [0.144-0.156] respectively, p<0.0001). Concentration of CgA, but not of VS-I, significantly increased in patients who died (n = 47) than in survivors (n = 143) (median 0.948 nM [IQR 0.514-1.754] vs 0.507 nM [IQR 0.343-0.785], p = 0.00026). Levels of CgA were independent predictors of in-hospital mortality (hazard ratio 1.28 [95% confidence interval 1.077-1.522], p = 0.005) when adjusted for age, number of comorbidities, respiratory insufficiency degree, C-reactive protein levels and time from symptom onset to sampling. Kaplan Meier curves revealed a significantly increased mortality rate in patients with CgA levels above 0.558 nM (median value, log rank test, p = 0.001).
Conclusion: Plasma CgA levels increase in COVID-19 patients and represent an early independent predictor of mortality.
